Related Experiment Video
Updated: May 20, 2026

Sub-acute Cerebral Microhemorrhages Induced by Lipopolysaccharide Injection in Rats
Published on: October 17, 2018
Cerebral microbleeds: a review
M Loitfelder1, S Seiler, P Schwingenschuh
1Department of Neurology, Medical University of Graz, Graz, Austria.
Abstract:
Cerebral microbleeds (CMBs) are frequent findings in MRI scans of elderly subjects. Depending on the MRI protocols applied 4.7% to 24.4% of community-based subjects show incidental CMBs. The rates reported for various types of ischemic strokes and intracerebral hemorrhages vary between 19.4% and 68.5%. Most studies also demonstrated CMBs in approximately one third of Alzheimer cases. A lobar distribution of CMBs is considered to relate to cerebral amyloid angiopathy, while CMBs located in the basal ganglia or in infratentorial brain regions are thought to relate to hypertensive vasculopathy. Besides age, hypertension, diabetes mellitus, and low serum cholesterol have so far been identified as risk factors for CMBs. Presence of an APOE ε4 allele is the only genetic factor that was consistently shown to increase the risk for CMB development. There are only few longitudinal studies on the predictive value of CMBs. For incident ischemic strokes and intracerebral hemorrhages hazard ratios of 4.48 and 50.2 have been reported. CMBs also doubled the risk for conversion to dementia in MCI patients, and there are indications for CMBs being possible predictors of increased mortality. Given the small number of longitudinal investigations with often small sample sizes the role of CMBs as predictors of disease needs to be further elucidated. CMBs were significantly more common in warfarin-treated stroke patients who developed intracerebral hemorrhages (ICH). These data are cross-sectional. They do not provide enough evidence to consider CMBs as a contraindication for antithrombotic agents in primary and secondary stroke prevention. CMBs are likely to unfavourably affect cognitive functioning. It remains to be determined if direct lesion-related effects are responsible for this finding or if CMBs are sole markers of more extensive tissue damage in the wake of cerebral small vessel disease leading to widespread visible but also non-visible tissue destruction with a high likelihood for cognitive consequences.
Insights
Cerebral microbleeds (CMBs) are common in older adults and linked to various neurological conditions. Further research is needed to fully understand their role as predictors of disease and cognitive decline.
Area of Science:
- Neurology
- Neuroradiology
- Geriatrics
Background:
- Cerebral microbleeds (CMBs) are frequently observed in elderly individuals via MRI scans.
- Prevalence rates vary, with incidental CMBs found in 4.7%-24.4% of community-based subjects and higher rates in stroke and Alzheimer's disease patients.
- CMB distribution suggests links to cerebral amyloid angiopathy (lobar) and hypertensive vasculopathy (basal ganglia/infratentorial).
Purpose of the Study:
- To review the current understanding of cerebral microbleeds (CMBs) in neurological conditions.
- To explore the identified risk factors and potential predictive value of CMBs.
- To discuss the implications of CMBs for cognitive function and disease progression.
Main Methods:
- Review of existing literature and cross-sectional studies on cerebral microbleeds (CMBs).
- Analysis of prevalence data across different populations and conditions.
- Examination of identified risk factors, including age, hypertension, diabetes, cholesterol, and APOE ε4 allele.
Main Results:
- Age, hypertension, diabetes, low cholesterol, and APOE ε4 allele are established risk factors for CMBs.
- Longitudinal studies suggest CMBs predict incident ischemic strokes (HR 4.48), intracerebral hemorrhages (HR 50.2), and dementia conversion in MCI (doubled risk).
- CMBs are associated with increased mortality risk and may negatively impact cognitive functioning.
Conclusions:
- Cerebral microbleeds (CMBs) are significant markers of cerebral small vessel disease with potential predictive value for major neurological events and cognitive decline.
- While associated with increased risks, current cross-sectional data do not contraindicate antithrombotic agents for stroke prevention.
- Further longitudinal investigations are crucial to elucidate the precise role of CMBs as disease predictors and their impact on cognitive outcomes.
Related Concept Videos
Hemorrhagic Stroke l: Introduction
Cerebral Edema ll: Pathophysiology
Hemorrhagic Stroke ll: Pathophysiology
The Blood-brain Barrier
Cerebral Edema l: Introduction

